Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis
Рекомендации по применению биомаркеров при аутоиммунных ревматических заболеваниях: анализ, основанный на доказательных данных
2018-11-05
SCID: 54.1/un8ew23p
Discuss with AI
autoimmune rheumatic diseasesbiomarkerscomplement activationcytokine dysregulationpersonalized therapy
Figures from the paper
Abstract (AI)
Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.
Key Findings
1
Biomarkers are needed to support early diagnosis and identify patients at highest risk of poor outcomes.
2
Clinical remission is achieved in fewer than 50% of patients with autoimmune rheumatic diseases, highlighting an unmet need for personalized treatment.
3
Combining biomarkers from different categories may enable more accurate diagnosis and treatment selection.
4
Despite substantial biomarker research, much of the evidence has not been integrated into routine clinical care; the work clarifies biomarkers’ roles in diagnosis, prognosis, and treatment guidance.
5
The paper distinguishes mechanistic, clinical disease, and therapeutic biomarkers as three major biomarker categories.
Research Object
biomarkers in autoimmune rheumatic diseases
Research Subject
the roles and clinical utility of biomarkers for diagnosis, outcome prediction, and treatment selection
Publication Details
Publication Date
2018-11-05
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest